Side Effects of Drugs Annual
A worldwide yearly survey of new data in adverse drug reactions
- 1st Edition, Volume 37 - November 6, 2015
- Latest edition
- Editor: Sidhartha D. Ray
- Language: English
Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions was first published in 1977, and has been continually published as a yearly update… Read more
Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions was first published in 1977, and has been continually published as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each Annual provides clinicians and medical investigators with a reliable and critical survey of new data and trends in the area of adverse drug reactions and interactions, with an international team of specialists contributing their expertise each year.
- Provides a critical yearly survey of the new data and trends regarding the side effects of drugs
- Authored and reviewed by pioneers throughout the world in the clinical and practice sciences
- Presents an essential clinical on the side effects of drugs for practitioners and healthcare professionals
Pharmacologists, clinicians, pharmaceutical companies, clinical toxicologists, clinical pharmacologists and medical libraries.
- I Introduction
- References on Adverse Drug Reactions
- II Pharmacogenomics Considerations
- References Pharmacogenomics Considerations
- III Immunological Reactions
- References
- IV Analysis of Toxicological Reactions
- References
- V Grades of Adverse Drug Reactions
- References
- VI FDA Pregnancy Categories/Classification of teratogenicity
- References
- Conclusion
- Abstract
- Methylxanthines
- Vigilance Promoting Drugs
- Parasympathomimetics [SEDA-32, 19; SEDA-33, 15; SEDA-34, 9]
- Abstract
- General
- Selective Serotonin Re-Uptake Inhibitors (SSRIs) [SED-15, 3109; SEDA-31, 18; SEDA-32, 33; SEDA-33, 26; SEDA-34, 17; SEDA-35, 30; SEDA-36, 14]
- Serotonin and Noradrenaline Re-Uptake Inhibitors (SNRIs)
- Other Antidepressants
- Abstract
- Introduction
- Organs and Systems
- Second-Generation Effects
- Susceptibility Factors
- Interactions
- Diagnosis of Adverse Drug Reactions
- Management of Adverse Drug Reactions
- Pharmacogenomics
- Abstract
- Introduction
- Cannabinoid
- Alcohol
- Benzodiazepines
- Sympathomimetics—Cocaine
- Opioids—Heroin
- Electronic Cigarettes (E-Cigarettes)
- Conclusion
- Abstract
- Benzodiazepines
- Hypnosedatives and Benzodiazepine-Like Drugs
- Abstract
- General [SEDA-15, 2438; SEDA-32, 83; SEDA-33, 89; SEDA-34, 51; SEDA-35, 85; SEDA-36, 59]
- Individual Drugs
- Acknowledgements
- Abstract
- Abstract
- Opioid Receptor Agonists
- Alfentanil [SED-15, 72; SEDA-34, 152; SEDA-35, 173; SEDA-36, 108]
- Codeine [SED-15, 880; SEDA -34, 152; SEDA-35, 174; SEDA-36, 108]
- Dextrometrophan [SED-15, 1088; SEDA-34, 153; SEDA-35, 174; SEDA-36, 108]
- Diamorphine [SED-15, 1096; SEDA-34, 153; SEDA-35, 175; SEDA-36, 108]
- Dihydrocodeine [SED-15, 1125; SEDA-34, 154; SEDA-35, 175; SEDA-36, 108]
- Fentanyl [SED-15, 1346; SEDA-34, 154; SEDA-35, 176; SEDA-36, 109]
- Hydrocodone [SED-15, 1702; SEDA-34, 156; SEDA-35, 177; SEDA-36, 109]
- Methadone [SED-15, 2270; SEDA-34, 157; SEDA-35, 177; SEDA-36, 110]
- Morphine [SED-15, 2386; SEDA-34, 159; SEDA-35, 181; SEDA-36, 111]
- Oxycodone [SED-15, 2651; SEDA-34, 161; SEDA-35, 182; SEDA-36, 111]
- Papaverine [SED-15, 2678; SEDA-34, 162; SEDA-35, 183; SEDA-36, 112]
- Pethidine (Meperidine) [SED-15, 2791; SEDA-34, 163; SEDA-35, 183; SEDA-36, 112]
- Remifentanyl [SED-15, 3030; SEDA-34, 163; SEDA-35, 184; SEDA-36, 112]
- Tramadol [SED-15, 3469; SEDA-34, 165; SEDA-35, 184; SEDA-36, 112]
- Partial Opioid Receptor Agonists
- Opioid Receptor Antagonists
- Naloxone [SED-15, 2421; SEDA-35, 186; SEDA-36, 114]
- Naltrexone [SED-15, 2423; SEDA-34, 168; SEDA-35, 186; SEDA-36, 114]
- Abstract
- Amidopyrine and Related Compounds [SEDA-34, 184; SEDA-35, 197]
- Aniline Derivatives [SED-15, 2679; SEDA-34, 184; SEDA-35, 197]
- Arylalkanoic Acid Derivatives [SED-15, 2555; SEDA-34, 185; SEDA-35, 200; SEDA-36, 119–120]
- COX-2 Selective Inhibitors [SEDA-34, 186; SEDA-35, 201; SEDA 36, 120]
- Indoleacetic Acids [SEDA-34, 187]
- Oxicams [SEDA-34, 187; SEDA-35, 201; SEDA-36, 126]
- Propionic Acid Derivatives [SEDA-36, 127]
- Salicylates [SED-15, 15; SEDA-34, 188; SEDA-35, 202; SEDA-36, 127]
- Miscellaneous Drugs
- Drugs Used in the Treatment of Gout
- Abstract
- Introduction
- Abstract
- General Information
- Combined Anesthetics
- Benzocaine
- Bupivacaine
- EMLA
- Levobupivacaine
- Lidocaine
- Oxybuprocaine
- Ropivacaine
- Abstract
- Depolarizing Neuromuscular Blocking Agents
- Non-Depolarizing Neuromuscular Blockers
- Neuromuscular Blockers: Reversal Agents
- Skeletal Muscle Relaxants
- Abstract
- Drugs that Stimulate Both Alpha- and Beta-Adrenoceptors [SEDA-33, 313; SEDA-34, 233; SEDA-35, 255; SEDA-36, 179]
- Drugs that Predominantly Stimulate Alpha 1-Adrenoceptors [SEDA-33, 318; SEDA-34, 236; SEDA-35, 257; SEDA-36, 186]
- Drugs that Stimulate β1-Adrenoceptors [SEDA-33, 265; SEDA-34, 285; SEDA-35, 257; SEDA-36, 187]
- Drugs that Stimulate β2-Adrenoceptors
- Drugs that Stimulate Dopamine Receptors [SEDA-33, 266; SEDA-34, 283; SEDA-35, 262; SEDA-36, 190]
- Drugs that Affect the Cholinergic System [SEDA-31, 272; SEDA-32, 290; SEDA-33, 324; SEDA-34, 290-1, 318; SEDA-35, 266; SEDA-36, 199]
- Abstract
- Introduction
- Acne
- Antifungals
- Hair Loss Treatment
- Pigmentation Disorders
- Psoriasis
- Cutaneous Side Effects from Antiviral Medications
- Cutaneous Side Effects from Cancer Medications
- Cutaneous Side Effects from Neurological Medications
- Individual Medications
- Abstract
- General
- Special Review on Pharmacogenetics
- Other Antihistamines
- Abstract
- Susceptibility Factors
- Interactions
- Long Acting Beta2-Adrenoceptor Agonists [SEDA-32, 314; SEDA-33, 357; SEDA-34, 280; SEDA 35, 315; SEDA-36, 245]
- Interactions
- Phosphodiesterase Inhibitors [SEDA-32, 321; SEDA-33, 367; SEDA-34, 284; SEDA-35, 321; SEDA-36, 252]
- Abstract
- Cardiac Glycosides [SED-15, 648; SEDA-34, 287; SEDA-35, 327; SEDA-36, 257]
- Special Review—Digoxin Use and Mortality in Atrial Fibrillation
- Other Positive Inotropes
- Antidysrhythmic Drugs
- Abstract
- Beta-Adrenoceptor Antagonists [SED-15, 452; SEDA-32, 363; SEDA-33, 397; SEDA-34, 303; SEDA-35, 351; SEDA-36, 267]
- Interactions
- Long-Term Effects
- Potassium Channel Activators
- Calcium Channel Blockers [SED-15, 598; SEDA-32, 366; SEDA-33, 401; SEDA-34, 306; SEDA-35, 354; SEDA-36, 270]
- Abstract
- Drugs Used in the Treatment of Arterial Disorders of the Brain and Limbs and in the Treatment of Migraine
- Second Generation Effects
- Drugs Used in the Treatment of Venous Disorders
- Other Peripheral Vasodilators
- Abstract
- Angiotensin-Converting Enzyme Inhibitors [SED-15, 226; SEDA-33, 416;SEDA-34, 321; SEDA-35,364, SEDA-36, 282]
- Angiotensin Receptor Blockers/Angiotensin II Receptor Antagonists [SEDA-15, 2071; SEDA-34, 324; SEDA-35; SEDA-36, 282]
- Calcium Channel Blockers
- Direct Renin Inhibitors [SEDA-33, 420; SEDA-34, 328; SEDA-35, 373; SEDA-36, 283]
- Direct Vasodilators [SEDA-36, 284]
- Dopamine Beta-Hydroxylase Inhibitor
- Drugs That Act on the Sympathetic Nervous System [SEDA-33, 424; SEDA-34, 329; SEDA-35, 376; SEDA-36, 286]
- Diuretics
- Endothelian Receptor Antagonists
- Prostacyclin Analog
- Pulmonary Vasodilators [SEDA-33, 421; SEDA-34, 328; SEDA-35, 374; SEDA-36, 284]
- Antihypertensives in Pregnancy
- Abstract
- Carbonic Anhydrase Inhibitors [SEDA-15, 643; SEDA-34, 339; SEDA-35, 387, SEDA-36, 289]
- Loop Diuretics [SEDA-15, 567, 1454; SEDA-34, 342; SEDA- 35, 390; SEDA-36, 290]
- Thiazide and Thiazide-Like Diuretics [SEDA-15, 3375; SEDA-34, 340; SEDA-35, 388; SEDA-36, 292]
- Aldosterone Receptor Antagonists
- Osmotic Diuretics
- Abstract
- Aluminium [SED-15, 97; SEDA-32, 413; SEDA-33, 447; SEDA-34, 349; SEDA-35, 397; SEDA-36, 297]
- Arsenic [SED-15, 339; SEDA-32, 414; SEDA-33, 448; SEDA-34, 351; SEDA-35, 399; SEDA-36, 298]
- Antimony and Antimonials [SED-15, 316; SEDA-32, 414; SEDA-33, 448; SEDA-34, 350; SEDA-35, 398; SEDA-36, 298]
- Beryllium [SEDA-34, 353; SEDA-35, 400; SEDA-36, 301]
- Calcium Salts [SED-15, 610; SEDA-33, 449; SEDA-34, 354; SEDA-35, 400; SEDA-36, 301]
- Chromium [SED-15, 737; SEDA-32, 414; SEDA-33, 450; SEDA-34, 354; SEDA-35, 401; SEDA-36, 303]
- Cobalt [SED-15, 847; SEDA-32, 415; SEDA-33, 450; SEDA-34, 354; SEDA-35, 402; SEDA-36, 303]
- Copper [SED-15, 901; SEDA-32, 415; SEDA-33, 450; SEDA-34, 355; SEDA-35, 402; SEDA-36, 304]
- Gold and Gold Salts [SED-15, 1520; SEDA-32, 416; SEDA-33, 451; SEDA-34, 355; SEDA-35, 402; SEDA-36, 305]
- Lanthanum Carbonate [SEDA-32, 417; SEDA-33, 451; SEDA-34, 356; SEDA-35, 404; SEDA-36, 306]
- Lead [SED-15, 2013; SEDA-28, 247; SEDA-35, 404; SEDA-36, 307]
- Iron Salts [SED-15, 1911; SEDA-32, 417; SEDA-33, 451; SEDA-34, 355; SEDA-35, 402; SEDA-36, 305]
- Magnesium Salts [SED-15, 2196; SEDA-32, 417; SEDA-33, 452; SEDA-34, 356; SEDA-35, 406; SEDA-36, 309]
- Mercury and Mercurial Salts [SED-15, 2259; SEDA-32, 419; SEDA-33, 453; SEDA-34, 358; SEDA-35, 407; SEDA-36, 311]
- Nickel [SED-15, 2502; SEDA-32, 419; SEDA-33, 453; SEDA-34, 358; SEDA-35, 409; SEDA-36, 313]
- Potassium Salts [SED-15, 2905; SEDA-31, 392; SEDA-35, 409; SEDA-36, 314]
- Strontium Salts [SEDA-32, 420; SEDA-33, 455; SEDA-34, 359; SEDA-35, 410; SEDA-36, 315]
- Silver Salts and Derivatives [SED-15, 3140; SEDA-32, 420; SEDA-33, 454; SEDA-34, 359; SEDA-35, 409; SEDA-36, 314]
- Titanium [SED-15, 3434; SEDA-32, 420; SEDA-33, 456; SEDA-34, 360; SEDA-35, 410; SEDA-36, 315]
- Zinc [SED-15, 3717; SEDA-32, 420; SEDA-33, 458; SEDA-34, 360; SEDA-35, 410; SEDA-36, 315]
- Abstract
- Introduction
- Deferasirox [SEDA-32, 426; SEDA-33, 466; SEDA-34, 368; SEDA-35, 420; SEDA-36, 323]
- Deferiprone [SEDA-15, 1054; SEDA-32, 427; SEDA-33, 468; SEDA-34, 370; SEDA-35, 422, SEDA-36, 327]
- Deferoxamine/Desferrioxamine [SEDA-15, 1058; SEDA-32, 429; SEDA-33, 471; SEDA-34, 371, SEDA-35, 423]
- Edetic Acid (EDTA) [SED-15, 1300; SEDA-31, 405; SEDA-32, 431; SEDA-33, 474; SEDA-35, 372]
- HQK-1001 (2,2-Dimethylbutyrate)
- Hydroxyurea [SEDA-36, 330]
- d-Penicillamine [SEDA-15, 2729; SEDA-32, 430; SEDA-33, 472; SEDA-34, 372; SEDA-35, 424; SEDA-36, 330]
- Trientine (Triethylenetetramine) [SEDA-15, 3508; SEDA-32, 431, SEDA-33, 474; SEDA-34, 373; SEDA-35, 427; SEDA-36, 333]
- Tiopronin [SED-15, 3430; SEDA-35, 373]
- Polystyrene Sulphonates [SEDA-15, 2894; SEDA-32, 433; SEDA-33, 474; SEDA-34, 373; SEDA-35, 427; SEDA-36, 333]
- Abstract
- All Commonly Used Antiseptics and Disinfectants
- Aldehydes [SED-15, 1439, 1513; SEDA-31, 409; SEDA-32, 437; SEDA-33, 479; SEDA-34, 377; SEDA-36, 339]
- Guanidines
- Benzalkonium Compounds [SED-15, 421; SEDA-32, 440; SEDA-33, 481; SEDA-34, 379; SEDA-36, 341]
- Ethylene Oxide [SED-15, 1296; SEDA-29, 242; SEDA-34, 379; SEDA-36, 341]
- Triclosan [SEDA-34, 379, SEDA-36, 342]
- Halogens
- Iodophors [SED-15, 1896; SEDA-31, 411; SEDA-32, 440; SEDA-33, 485; SEDA-34, 380; SEDA-36, 342]
- Abstract
- Carbapenems
- Cephalosporins
- Monobactams
- Penicillins
- Tetracyclines and Glycylcyclines
- Abstract
- Aminoglycosides [SED-15, 118; SEDA-32, 461; SEDA-33, 509; SEDA-34, 399; SEDA 35, 463; SEDA-36, 363]
- Fluoroquinolones [SEDA-15, 1396; SEDA-32, 464; SEDA-33, 514; SEDA-34, 401; SEDA-36, 464; SEDA-36, 365]
- Glycopeptides [SEDA-32, 469; SEDA-33, 519; SEDA-34, 405; SEDA-35, 466, SEDA-36, 368]
- Ketolides [SED-15, 1976; SEDA-32, 471; SEDA-33, 521; SEDA-34, 407; SEDA-35, 469; SEDA-36, 370]
- Lincosamides [SED-15, 2063; SEDA-32, 472; SEDA-33, 522; SEDA-34, 407; SEDA-35, 469; SEDA-36, 371]
- Macrolides [SED-15, 2183; SEDA-32, 472; SEDA-33, 522; SEDA-34, 408; SEDA-35, 469; SEDA-36, 371]
- Oxazolidinones [SED-15, 2645; SEDA-32, 474; SEDA-33, 525; SEDA-34, 409; SEDA-35, 471; SEDA-36, 373]
- Polymyxins [SED-15, 2891; SEDA-32, 476; SEDA-33, 527; SEDA-34, 412; SEDA-35, 473; SEDA-36, 374]
- Streptogramins [SED-15, 3182; SEDA-32, 528; SEDA-34, 413; SEDA-35, 473; SEDA-36, 375]
- Trimethoprim and Co-Trimoxazole [SED-15, 3216, 3510; SEDA-32, 477; SEDA-33, 528; SEDA-34, 414; SEDA-35, 474; SEDA-36, 375]
- Other Antimicrobial Drugs
- Abstract
- Allylamines [SEDA-34, 427; SEDA-35,483; SEDA-36, 381]
- Amphotericin [SEDA-33, 542; SEDA-34, 427; SEDA-35,483; SEDA-36, 382]
- Antifungal Azoles [SEDA-33, 545; SEDA-34, 428; SEDA-35, 484; SEDA-36, 382]
- Pyrimadine Analogues [SEDA-36, 383]
- Echinocandins [SEDA-33,556; SEDA-34,434; SEDA-35,489; SEDA-36, 388]
- Anidulafungin [SEDA-35,489; SEDA-36, 388]
- Caspofungin [SEDA-33, 556; SEDA-34, 434; SEDA-35,490; SEDA-36, 389]
- Abstract
- Introduction
- Albendazole
- Artemether–Lumefantrine
- Dihydroartemisinin–Piperaquine
- Fexinidazole
- Fumagillin
- Nitazoxanide
- Oxantel Pamoate–Albendazole
- Posaconazole
- Primaquine
- Quinacrine
- Tafenoquine–Chloroquine
- Thiamine Hydrochloride
- Trimethoprim–Sulfamethoxazole
- Artesunate
- Mefloquine
- Acetazolamide
- Abstract
- Drugs Active Against Cytomegalovirus
- Drugs Active Against Herpes Viruses [SEDA-32, 530; SEDA-33, 577; SEDA-34, 450, SEDA-35, 507, SEDA-36, 407]
- Drugs Active Against Hepatitis Viruses
- Direct-Acting Antiviral Protease Inhibitors [SEDA-35, 508; SEDA-36, 409]
- Drugs Active Against Human Immunodeficiency Virus: Combinations
- Drugs Active Against Human Immunodeficiency Virus: Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI) [SED-15, 2586; SEDA-32, 534; SEDA-33, 585; SEDA-34, 456; SEDA-35, 516; SEDA-36, 415]
- Drugs Active Against Human Immunodeficiency Virus: Nucleotide Analogue Reverse Transcriptase Inhibitors
- Drugs Active Against Human Immunodeficiency Virus: Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) [SED-15, 2553; SEDA-31, 486; SEDA-32, 537; SEDA-33, 590; SED-34, 459; SEDA-35, 519; SEDA-36, 420]
- Drugs Active Against Human Immunodeficiency Virus: Protease Inhibitors [SED-15, 2586; SEDA-32, 541; SEDA-33, 593; SEDA-34, 461, SEDA-35, 522; SEDA-36, 423]
- Drugs Active Against Human Immunodeficiency Virus: Inhibitors of HIV Fusion [SEDA-33; 598; SEDA-34, 464; SEDA-35, 525; SEDA-36, 428]
- Drugs Active Against Human Immunodeficiency Virus: Chemokine Receptor CCR5 Antagonists [SEDA-33, 600; SEDA 34, 465; SEDA-35, 528; SEDA-36, 430]
- Drugs Active Against Influenza Viruses: Ion Channel Inhibitors [SED-15, 105, 3051; SEDA-32, 544; SEDA-33, 269, 602; SEDA-34, 467; SEDA-35, 529; SEDA-36, 430]
- Drugs Active Against Influenza Viruses: Neuraminidase Inhibitors [SED-15, 2436; SEDA-32, 544; SEDA-33, 601; SEDA-34, 466; SEDA-35, 528; SEDA-36, 431]
- Other Drugs
- Abstract
- Rifamycins
- Bedaquiline
- Linezolid
- Isoniazid
- Ethambutol
- Fluoroquinolones
- Pyrazinamide
- Clofazimine
- Cycloserine
- Delamanid
- Dapsone
- Streptomycin
- Abstract
- Albendazole (SEDA-31, 508; SEDA-32, 572; SEDA-33, 647; SEDA-36, 458)
- Ivermectin (SEDA-31, 509; SEDA-32, 575; SEDA-33, 649; SEDA-36, 460)
- Levamisole (SEDA-31, 510; SEDA-32, 575; SEDA-33, 649; SEDA-36, 460)
- Mebendazole (SEDA-36, 461)
- Praziquantel (SEDA-31, 511; SEDA-33, 650; SEDA-36, 461)
- Tribendimidine (SEDA 36, 462)
- Abstract
- General [SEDA-36, 465]
- Viral Vaccines
- Bacterial Vaccines
- Abstract
- Albumin and Derivatives [SEDA-15, 54; SEDA-33, 670; SEDA-34, 509; SEDA-35, 583;SEDA-36, 483]
- Blood Transfusion [SEDA-15, 529; SEDA-34, 509; SEDA-35, 583, SEDA-36, 483]
- Blood Substitutes [SEDA-33, 672; SEDA-34, 511; SEDA-35, 586; SEDA-36, 485]
- Plasma and Plasma Products [SEDA-15, 84; SEDA-34, 512; SEDA-35, 586, SEDA-36, 486]
- Plasma Substitutes [SEDA-33, 675; SEDA-34, 513; SEDA-35, 587; SEDA-36, 487]
- Globulins
- Coagulation Proteins [SEDA-15, 845; SEDA-33, 679; SEDA-34, 518; SEDA-36, 493]
- Erythropoietin and Derivatives [SEDA-34, 520; SEDA-35, 594; SEDA-36, 494]
- Thrombopoietin and Receptor Agonists [SEDA-15, 3409; SEDA-36-495]
- Transmission of Infectious Agents Through Blood Donation [SEDA-34, 521; SEDA-35,596; SEDA-36, 495]
- Stem Cells [SEDA-34, 522; SEDA-35, 597; SEDA-36, 496]
- Abstract
- Coumarin Anticoagulants [SED-15, 983; SEDA-34, 541; SEDA-35, 617; SEDA-36, 529]
- Heparins [SED-15, 1590; SEDA-34, 543; SEDA-35, 618; SEDA-36, 530]
- Direct Thrombin Inhibitors [SED-15, 1142; SEDA-34, 544; SEDA-35, 619; SEDA-36, 531]
- Direct Factor XA Inhibitors [SEDA-34, 546; SEDA-35, 620; SEDA-36, 532]
- Thrombolytic Drugs [SEDA-15, 3402; SEDA-35, 621; SEDA-36, 532]
- Glycoprotein IIb–IIIa Inhibitors [SED-15, 2849; SEDA-33, 720; SEDA-34, 548; SEDA-35, 622]
- P2Y12 Receptor Antagonists [SED-15, 821; SEDA-34, 548; SEDA-35, 622; SEDA-36, 533]
- Hemostatic Agents [SEDA-34, 549; SEDA-35, 624; SEDA-36, 536]
- Abstract
- Acid-Impacting Agents
- Anticonstipation and Prokinetic Agents
- Antidiarrheal and Antispasmotic Agents
- Antiemetic Agents
- Anti-inflammatory Agents
- Biologics
- Steroids
- Abstract
- Cytokines
- Interferons [SEDA-32, 676; SEDA-33, 773; SEDA-34, 581; SEDA-35, 660; SEDA-36, 564]
- Interleukins [SEDA-33, 777; SEDA-34, 771; SEDA-36, 567]
- Monoclonal Antibodies
- Abstract
- Belatacept [SEDA 34–609]
- Cyclophosphamide [SED-15, 1025; SEDA-34, 612; SEDA-35, 700; SEDA-36, 592]
- Special Reviews - Cyclosporine (Ciclosporin) [SED-15, 743; SEDA-34, 609; SEDA-35, 699; SEDA-36, 591]
- Everolimus [SED-15, 1306; SEDA-34, 614; SEDA-35, 701; SEDA 36, 592]
- Fingolimod [SEDA-34, 616; SEDA-35, 703; SEDA-36, 593]
- Glatiramer [SEDA-34, 617; SEDA-35, 703; SEDA-36]
- Leflunomide [SED-15, 2015; SEDA-34, 618; SEDA-35, 703; SEDA-36, 594]
- Mycophenolic Acid [SED-15, 2402; SEDA-34, 622; SEDA-35, 704; SEDA-36, 594]
- Sirolimus (Rapamycin) [SED-15, 3148; SEDA-34, 626; SEDA-35, 705; SEDA-36, 594]
- Tacrolimus [SED-15, 3279; SEDA-34, 629; SEDA-35, 705; SEDA-36, 596]
- Temsirolimus [SEDA-34, 632; SEDA-35, 707; SEDA-36, 597]
- Thiopurines [SED-15, 377; SEDA-34, 633; SEDA-35, 709; SEDA-36, 598]
- Voclosporin
- Immunoenhancing Drugs
- Abstract
- Corticotrophins [SED-15, 906; SEDA-33, 841; SEDA-34, 653; SEDA-35, 719; SEDA-36, 603]
- Systemic Glucocorticoids [SED-15, 906; SEDA-33, 841; SEDA-34, 653; SEDA-35, 719; SEDA-36, 604]
- Prostaglandins and Analogues [SED-15, 2955; SEDA-33, 846; SEDA-34, 660; SEDA-35, 725]
- Abstract
- Estrogens [SED-15, 1253; SEDA-34, 663; SEDA-35, 731; SEDA-36, 615]
- Hormone Replacement Therapy [SED-15, 1684, 1686, 1692; SEDA-34, 666; SEDA-35, 732; SEDA-36, 616]
- Hormonal Contraceptives [SED-15, 1642, 1645; SEDA-34, 667; SEDA-35, 733; SEDA-36, 618]
- Anti-Estrogens and Selective Estrogen Receptor Modulators [SEDA-34, 669; SEDA-35, 735; SEDA-36, 619]
- Progestogens [SED-15, 2930; SEDA-34, 671; SEDA-35, 736; SEDA-36, 622]
- Progesterone Antagonists [SEDA-34, 671; SEDA-35, 738; SEDA-36, 625]
- Anabolic Steroids, Androgens and Related Compounds [SED-15, 216; SEDA-34, 672; SEDA-35, 738; SEDA-36, 627]
- Antiandrogens [SEDA-34, 674; SEDA-35, 740; SEDA-36, 628]
- Acknowledgements
- Abstract
- Thyroid Hormones [SED-15, 3409; SEDA-31, 687; SEDA-32, 763; SEDA-33, 881; SEDA-34, 679; SEDA-35, 747; SEDA-36, 635]
- Iodine and Iodides [SED-15, 1896; SEDA-32, 764; SEDA-33, 883; SEDA-34, 680; SEDA-35, 752; SEDA-36]
- Antithyroid Drugs [SEDA-32, 765; SEDA-33, 884; SEDA-34, 681; SEDA-35, 754, SEDA-36, 638]
- Abstract
- Abstract
- Introduction
- Calcitonin [SEDA-34, 703; SEDA-35, 789; SEDA-36, 659]
- Gonadotropins (Gonadorelin, GnRH and Analogues) [SEDA-35, 789; SEDA-36, 660]
- Gonadotrophin-Releasing Hormone Antagonists [SEDA-35, 790; SEDA-36, 661]
- Special Review - Somatropin (Human Growth Hormone, hGH) [SEDA-35, 791; SEDA-36, 661]
- Growth Hormone Receptor Antagonists [SEDA-34, 708; SEDA-35, 792; SEDA-36, 664]
- Melatonin and Analogues [SED-15, 2245; SEDA-35, 792; SEDA-36, 664]
- Oxytocin and Analogues [SEDA-35, 793; SEDA-36, 665]
- Parathyroid Hormone and Analogues [SEDA-34, 711; SEDA-35, 794; SEDA-36, 661]
- Somatostatin (Growth Hormone Release-Inhibiting Hormone) and Analogues [SED-15, 3160; SEDA-35, 794; SEDA-36, 666]
- Octreotide and Octreotide Long-Acting Release (LAR)
- Pasireotide
- Vasopressin Receptor Antagonists [SEDA-34, 713; SEDA-35, 797; SEDA-36, 668]
- Vasopressin and Analogues [SEDA-33, 915; SEDA-34, 714; SEDA-35, 798; SEDA-36, 669]
- Terlipressin [SEDA-34, 714; SEDA-35, 798; SEDA-36, 669]
- Vasopressin [SEDA-34, 715; SEDA-35, 798; SEDA-36, 669]
- Abstract
- Abstract
- Introduction
- Pyrimidine Analogues
- Azacitidine (5-Azacitidine)
- Cytarabine
- Decitabine
- Gemcitabine
- Fluoropyrimidines
- Fluorouracil
- Capecitabine
- Acknowledgement
- Abstract
- Drug Interactions
- MRI Contrast Media
- Ultrasound Contrast Agents [SEDA-32, 855; SEDA-33, 971; SEDA-34, 758; SEDA-35, 869; SEDA-36, 703]
- Abstract
- Introduction
- Traditional Chinese Herbal Medicine Preparations
- Herbal Medicine
- Green Tea Nutritional Supplements
- Specific Plants
- Acupuncture
- Cupping
- Moxibustion
- Osteopathy
- Tai Chi
- Tui Na
- Yoga
- Abstract
- Long-Term Effects
- Benzyl Alcohol (Preservative)
- Edition: 1
- Latest edition
- Volume: 37
- Published: November 6, 2015
- Language: English
SR
Sidhartha D. Ray
Sidhartha D. Ray, PhD, FACN serves as a Senior Professor of Pharmaceutical and Biomedical Sciences at The Touro College of Pharmacy at Manhattan, New York. Prior to this he served as Professor of Pharmaceutical Sciences for nearly 2 decades at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University, New York, and as the founding chair of Pharmaceutical Science department at Manchester University College of Pharmacy, Indiana, USA. He has been in the health sciences academy for over 35 years mainly focusing on pharmacy teaching, research and service. Dr. Ray's research program focus on drug & chemical induced organ toxicology, mechanistic & molecular toxicology, adverse drug reaction mechanisms, side effects of a number of therapeutically relevant drugs and environmentally significant chemicals. Over the last two decades, Dr. Ray’s seminal discoveries have provided clear understandings on the dynamic role of apoptosis, necrosis and necraptosis during organotoxic reactions and have influenced the development of safety measures for a stunning variety of xenobiotics, phytochemicals and nutraceuticals. He is internationally recognized as a leader in the scientific community and was one of the front runners in exploring mechanisms of drug and chemical-induced programmed and un-programmed cell death in in-vivo models. His landmark studies on the interplay of bcl-2, bcl-xl, p53, bad and bax during acetaminophen induced cell death and its prevention by grape seed proanthocyanidin extract has earned worldwide citations. His peer recognition and acknowledged service contributions are reflected by his election into multiple international professional organizations, such as the Society of Toxicology (SOT), Society of Free Radical Biology & Medicine (SFRBM), American Society of Pharmacology & Experimental Therapeutics (ASPET), American Association of Colleges of Pharmacy (AACP) and American College of Nutrition (ACN). Dr. Ray is an Associate Editor of Encyclopedia of Toxicology (3rd Ed, Elsevier, 2014), and serves on the editorial boards of multiple prestigious international journals, including ‘Archives of Toxicology’ and ‘Oxidative Medicine & Cellular Longevity’.
Based on his contributions to teaching, service and scholarship to health sciences in general, Dr. Ray received multiple prestigious awards, inc. the American Academy of Clinical Toxicology’s national research award (1996), ‘Fellow of the American College of Nutrition’ honor in 1999, David Newton Award for Excellence in Teaching Pharmacy (2005), the Biennial Abraham Krasnoff Memorial Award for Lifetime Scholarly Achievement (2008), Arnold & Marie Schwartz College of Pharmacy & Health Science’s ‘Wall-of-Fame’ honor (2011), the Society of Toxicology’s ‘Undergraduate Educator of the Year’ national award (2013), and the Manchester University’s ‘Outstanding Scholar of the Year’ award (2014). He currently serves on the SOT-NIH–NLM’s joint Toxlearn Project, SOT Undergraduate Task Force (2007 – present), and has previously served on the SOT’s Education Committee (2007 – 2010). In his lifetime, Dr. Ray has mentored research to numerous PharmD, MS, MD and PhD students in a number of areas of toxicology and biomedical sciences, made seminal contributions to the fields of pharmacology, toxicology, free radical biology, anticancer mechanism, phytochemicals, nutraceuticals & dietary supplements, and molecular safety sciences. Dr. Ray loves to promote ‘Lifelong Learning’ strategies to his students and clearly models his beliefs day in and day out. Visit URL: www.sidhartharay.com/ for more details.
Affiliations and expertise
Senior Professor of Pharmaceutical and Biomedical Sciences, Touro College of Pharmacy, Touro University System, Manhattan, NY, USARead Side Effects of Drugs Annual on ScienceDirect